Role of the MDM2-p53 Pathway in BTC

CME

Targeting the MDM2-p53 Pathway in Biliary Tract Cancer: Emerging Data and Implications for Future Clinical Practice

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 29, 2024

Expiration: February 28, 2025

Patricia LoRusso
Patricia LoRusso, DO, PhD(h)

Activity

Progress
1 2
Course Completed

Introduction

In this module, Patricia LoRusso, DO, PhD(h) reviews the current guidelines and recommendations for molecular testing in advanced biliary tract cancer (BTC) and puts into context the rationale for targeting MDM2/p53 signaling in BTC with a review of how the most relevant and up-to-date data on an emerging novel agent targeting this pathway in BTC may improve outcomes for patients in the future.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with BTC do you provide care for in a typical month?

What is the approximate incidence of MDM2 alterations found in BTC?

Which of the following were reported as the most common grade ≥3 treatment-related adverse events associated with the MDM2 inhibitor brigimadlin targeting the MDM2/p53 pathway in BTC?

The single-arm phase II Brightline-2 trial is investigating brigimadlin for patients with advanced BTC or other solid tumors harboring which of the following genetic aberrations?